Evidence map›Paper›PMID 28035494›Full record

ReviewJournal of bone and mineral metabolism2017

Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw.

Japanese Allied Committee on Osteonecrosis of the Jaw, Toshiyuki Yoneda, Hiroshi Hagino, Toshitsugu Sugimoto, Hiroaki Ohta, Shunji Takahashi, Satoshi Soen, Akira Taguchi, Toshihiko Nagata, Masahiro Urade and 2 more

Erratum issued Registry-linked trialAbstract readReviewConsensus Statement
PubMed Publisher
In one paragraph

Review in Journal of bone and mineral metabolism, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04584840 (Conservative Versus Surgical Treatment for Medication Related Osteonecrosis of the Jaws), which is not on this map. Cited by 150 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
150citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04584840 naunknown statusnot on this mapstarted 2020, after this paper: background citation

Conservative Versus Surgical Treatment for Medication Related Osteonecrosis of the Jaws (MRONJ) Stages I and II, a Quasi-experimental Clinical Trial With Discovery of Salivary Biomarkers

TypeinterventionalSponsorFundació d'investigació Sanitària de les Illes BalearsRan2020 to 2024Enrolled50ConditionsOsteonecrosis of the Jaw, Bisphosphonate Induced, Osteonecrosis of the Jaw, Bisphosphonate RelatedArmsSurgical treatment
3 · Its place in the literature

Who cites it

150 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Long-term oral bisphosphonates delay healing after tooth extraction: a single institutional prospective study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2018
    Trial
  7. Article
  8. Management of MRONJ: comparison between SIPMO-SICMF and AAOMS consensus statements and clinical-economic implications for the national health system.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. [Expert consensus on perioperative management of tooth extraction in patients receiving denosumab therapy].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2026
    Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

90 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Japanese Allied Committee on Osteonecrosis of the Jaw
Toshiyuki YonedaDivision of Hematology and Oncology, Indiana University School of Medicine, Indianapolis, USA. toshyone@iu.edu.
Hiroshi HaginoSchool of Health Science, Faculty of Medicine, Tottori University, Tottori, Japan.
Toshitsugu SugimotoInternal Medicine 1, Shimane University Faculty of Medicine, Matsue, Japan.
Hiroaki OhtaClinical Research Centers for Medicine, International University of Health and Welfare, Ohtawara, Japan.
Shunji TakahashiDepartment of Medical Oncology, The Cancer Institute Hospital Of Japanese Foundation of Cancer Research, Tokyo, Japan.
Satoshi SoenDepartment of Orthopaedic Surgery and Rheumatology, Kindai University Nara Hospital, Ikoma, Japan.
Akira TaguchiDepartment of Hard Tissue Research, Graduate School of Oral Medicine, Matsumoto Dental University, Shiojiri, Japan.
Toshihiko NagataDepartment of Periodontology and Endodontology, School of Dentistry, Tokushima University, Tokushima, Japan.
Masahiro UradeDepartment of Oral and Maxillofacial Surgery, Hyogo College of Medicine, Nishinomiya, Japan.
Takahiko ShibaharaDepartment of Oral and Maxillo-Facial Surgery, Tokyo Dental College, Tokyo, Japan.
Satoru ToyosawaDepartment of Oral Pathology, Osaka University Graduate School of Dentistry, Suita, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) is an intractable, though rare, complication in cancer patients with bone metastases and patients with osteoporosis who are treated with antiresorptive agents, including bisphosphonates and denosumab. Despite the more than 10 years that have passed since the first cases of bisphosphonate-related osteonecrosis of the jaw (BRONJ) were reported, our understanding of the epidemiology and pathophysiology of ARONJ remains limited, and data supported by evidence-based medicine are still sparse. However, the diagnosis and staging of ARONJ, identification of risk factors, and development of preventive and therapeutic approaches have advanced significantly over the past decade. The Position Paper 2017 is an updated version of the Position Paper 2010 of the Japanese Allied Committee on Osteonecrosis of the Jaw, which now comprises six Japanese academic societies. The Position Paper 2017 describes a new diagnostic definition for ARONJ, as proposed by the American Association of Oral and Maxillofacial Surgeons (AAOMS), summarizes our current understanding of the pathophysiology of ARONJ based on a literature search, and suggests methods for physicians and dentists/oral surgeons to manage the disease. In addition, the appropriateness of discontinuing antiresorptive medications (drug holiday) before, during, and after invasive dental treatments is discussed extensively. More importantly, the manuscript also proposes, for the first time, the importance of interactive communication and cooperation between physicians and dentists/oral surgeons for the successful treatment of ARONJ. The Position Paper 2017 is intended to serve as a guide for improving the management of ARONJ patients in Japan.

Indexed as

Evidence-Based MedicineAsian PeopleBisphosphonate-Associated Osteonecrosis of the JawFemaleHumansJapanMalePeriodicals as TopicPractice Guidelines as TopicBisphosphonatesDenosumabDrug holidaysOral bacterial infectionOsteonecrosis of the jawTeam therapeutic approaches

Identifiers

PMID28035494

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.